The First, Comprehensive Immunological Model of COVID-19: Implications for Prevention, Diagnosis, and Public Health Measures

The natural history of COVID-19 caused by SARS-CoV-2 is extremely variable, ranging from asymptomatic infection, to pneumonia, and to complications eventually fatal. We propose here the first model, explaining how the outcome of first, crucial 10-15 days after infection, hangs on the balance between the cumulative dose of viral exposure and the efficacy of the local innate immune response (natural IgA and IgM antibodies, MBL). If SARS-CoV-2 runs the blockade of this innate immunity and spreads from the upper airways to the alveoli in the early phases of the infections, it can replicate with no local resistance, causing pneumonia and releasing high amounts of antigens. The delayed and strong adaptive immune response (high affinity IgM and IgG antibodies) that follows, causes severe inflammation and triggers mediator cascades (complement, coagulation, and cytokine storm) leading to complications often requiring intensive therapy and being, in some patients, fatal. Strenuous exercise and high flow air in the incubation days and early stages of COVID-19, facilitates direct penetration of the virus to the lower airways and the alveoli, without impacting on the airway’s mucosae covered by neutralizing antibodies. This allows the virus to bypass the efficient immune barrier of the upper airways mucosa in young and healthy athletes. In conclusion, whether the virus or the adaptative immune response reach the lungs first, is a crucial factor deciding the fate of the patient. This “quantitative and time - sequence dependent” model has several implications for prevention, diagnosis, and therapy of COVID-19.

[1]  V. Lougaris,et al.  A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.

[2]  Mario Plebani,et al.  Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics , 2020, Clinical chemistry and laboratory medicine.

[3]  Shu-Yuan Xiao,et al.  Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies , 2020, Modern Pathology.

[4]  Dong Yang,et al.  Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Loosemore,et al.  Respiratory health in athletes: facing the COVID-19 challenge , 2020, The Lancet Respiratory Medicine.

[6]  R. McIntyre,et al.  Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series , 2020, Journal of Thrombosis and Haemostasis.

[7]  Wayne T. Nicholson,et al.  Deployment of convalescent plasma for the prevention and treatment of COVID-19. , 2020, The Journal of clinical investigation.

[8]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[9]  M. Nishimura,et al.  Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations , 2020, The Lancet Respiratory Medicine.

[10]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[11]  Matthias Klein,et al.  Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients , 2020, medRxiv.

[12]  A. Vespignani,et al.  Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study , 2020, The Lancet Infectious Diseases.

[13]  A. Zangrillo,et al.  Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis , 2020, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[14]  Heidi Ledford How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments , 2020, Nature.

[15]  M. Belingheri,et al.  Beyond the assistance: additional exposure situations to COVID-19 for healthcare workers , 2020, Journal of Hospital Infection.

[16]  Wei Chen,et al.  Extensive Acute Lower Extremity Arterial Thrombosis: A Major Thrombus Formation Caused by COVID-19 , 2020, medRxiv.

[17]  Daniel Wrapp,et al.  Site-specific analysis of the SARS-CoV-2 glycan shield , 2020, bioRxiv.

[18]  Xiang Yao,et al.  Knowledge synthesis from 100 million biomedical documents augments the deep expression profiling of coronavirus receptors , 2020, bioRxiv.

[19]  J. Dudley,et al.  Disparities in Age-Specific Morbidity and Mortality from SARS-CoV-2 in China and the Republic of Korea , 2020, medRxiv.

[20]  J. Guarner,et al.  Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. , 2020, JAMA.

[21]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[22]  Jon Brassey,et al.  SARS-CoV-2 viral load and the severity of COVID-19 , 2020 .

[23]  Guohong Deng,et al.  Viral Kinetics and Antibody Responses in Patients with COVID-19 , 2020, medRxiv.

[24]  Qi Jin,et al.  Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Beijing China. Prevention,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China , 2020 .

[26]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[27]  G. Wong,et al.  SARS-CoV-2 Infection in Children , 2020, The New England journal of medicine.

[28]  Lei Liu,et al.  Relationship between the ABO Blood Group and the COVID-19 Susceptibility , 2020, medRxiv.

[29]  Zhongyi Jiang,et al.  Epidemiology of COVID-19 Among Children in China , 2020, Pediatrics.

[30]  Arturo Casadevall,et al.  The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.

[31]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[32]  Tobias Bleicker,et al.  Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster , 2020, medRxiv.

[33]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[34]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[35]  Z. Memish,et al.  Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak , 2020, International Journal of Infectious Diseases.

[36]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[37]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[38]  Dapeng Zhou,et al.  Accessible Surface Glycopeptide Motifs on Spike Glycoprotein of 2019-nCoV: Implications on Vaccination and Antibody Therapeutics , 2020 .

[39]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[40]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[41]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[42]  Denisa Bojkova,et al.  Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China , 2020, The New England journal of medicine.

[43]  D. Heymann,et al.  COVID-19: what is next for public health? , 2020, The Lancet.

[44]  Christian Drosten,et al.  Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.

[45]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[46]  N. Linton,et al.  Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data , 2020, medRxiv.

[47]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[48]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[49]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[50]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[51]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[52]  J. Gildersleeve,et al.  Anti-glycan IgM repertoires in newborn human cord blood , 2019, PloS one.

[53]  T. Rothstein,et al.  Human B-1 Cells and B-1 Cell Antibodies Change With Advancing Age , 2019, Front. Immunol..

[54]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[55]  Jack C. Yu,et al.  Innate Immunity of Neonates and Infants , 2018, Front. Immunol..

[56]  V. Corman,et al.  Hosts and Sources of Endemic Human Coronaviruses , 2018, Advances in Virus Research.

[57]  J. Pruijt,et al.  Truly selective primary IgM deficiency is probably very rare , 2018, Clinical and experimental immunology.

[58]  A. Aghamohammadi,et al.  Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management , 2017, Scandinavian journal of immunology.

[59]  D. Kleinert,et al.  The role of complement activation in thrombosis and hemolytic anemias. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[60]  J. Kearney,et al.  Manipulation of the glycan‐specific natural antibody repertoire for immunotherapy , 2016, Immunological reviews.

[61]  Saddam M Muthana,et al.  Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum , 2016, Scientific Reports.

[62]  G. Castaldo,et al.  Biological role of mannose binding lectin: From newborns to centenarians. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[63]  J. Neuhaus,et al.  Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study , 2015, Critical Care.

[64]  B. Bertin,et al.  Role of mannose-binding lectin in intestinal homeostasis and fungal elimination , 2015, Mucosal Immunology.

[65]  K. Koenig Identify-Isolate-Inform: A Modified Tool for Initial Detection and Management of Middle East Respiratory Syndrome Patients in the Emergency Department , 2015, The western journal of emergency medicine.

[66]  L. Cooling Blood Groups in Infection and Host Susceptibility , 2015, Clinical Microbiology Reviews.

[67]  T. Hoffmann,et al.  Exercise versus no exercise for the occurrence, severity and duration of acute respiratory infections. , 2015, The Cochrane database of systematic reviews.

[68]  W. Liu,et al.  Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection , 2015, Journal of Infection.

[69]  Saddam M Muthana,et al.  Competition between Serum IgG, IgM, and IgA Anti-Glycan Antibodies , 2015, PloS one.

[70]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[71]  D. Wilkes,et al.  Complement system in lung disease. , 2014, American journal of respiratory cell and molecular biology.

[72]  Christian Drosten,et al.  Serological assays for emerging coronaviruses: Challenges and pitfalls , 2014, Virus Research.

[73]  V. Ziaee,et al.  Common Sports-Related Infections: A Review on Clinical Pictures, Management and Time to Return to Sports , 2014, Asian journal of sports medicine.

[74]  T. Fujita,et al.  Structural and Functional Overview of the Lectin Complement Pathway: Its Molecular Basis and Physiological Implication , 2013, Archivum Immunologiae et Therapiae Experimentalis.

[75]  J. Vaupel,et al.  Activity of mannose‐binding lectin in centenarians , 2012, Aging cell.

[76]  N. Baumgarth,et al.  B‐1 cells in the bone marrow are a significant source of natural IgM , 2012, European journal of immunology.

[77]  P. Bruneval,et al.  A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[78]  J. Otter,et al.  Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment , 2011, Food and Environmental Virology.

[79]  E. Schmidt,et al.  High-Dose Mannose-Binding Lectin Therapy for Ebola Virus Infection , 2011, The Journal of infectious diseases.

[80]  F. Polack,et al.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes , 2010, Nature Medicine.

[81]  J. Pedrosa,et al.  Influenza Infectious Dose May Explain the High Mortality of the Second and Third Wave of 1918–1919 Influenza Pandemic , 2010, PloS one.

[82]  J. Sung,et al.  Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza , 2009, The Journal of infectious diseases.

[83]  D. Eisen Mannose-Binding Lectin Deficiency and Respiratory Tract Infection , 2009, Journal of Innate Immunity.

[84]  Véronique Sébille,et al.  Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies , 2008, Glycobiology.

[85]  J. Balzarini Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy , 2007, Nature Reviews Microbiology.

[86]  M. Carroll,et al.  Natural Antibody and Complement Mediate Neutralization of Influenza Virus in the Absence of Prior Immunity , 2007, Journal of Virology.

[87]  C. Franceschi,et al.  A Study of Serum Immunoglobulin Levels in Elderly Persons That Provides New Insights into B Cell Immunosenescence , 2006, Annals of the New York Academy of Sciences.

[88]  Raymond Tellier,et al.  Review of Aerosol Transmission of Influenza A Virus , 2006, Emerging infectious diseases.

[89]  N. Klein,et al.  Mannose‐binding lectin in innate immunity: past, present and future , 2006, Tissue antigens.

[90]  H. Vollmers,et al.  Natural IgM antibodies: the orphaned molecules in immune surveillance. , 2006, Advanced drug delivery reviews.

[91]  Fuchu He,et al.  Association between Mannose-Binding Lectin Gene Polymorphisms and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.

[92]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[93]  H. Gewurz,et al.  Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. , 2005, The Journal of general virology.

[94]  J. Peiris,et al.  Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.

[95]  J. Sung,et al.  ABO blood group and susceptibility to severe acute respiratory syndrome. , 2005, JAMA.

[96]  Takeshi Kurata,et al.  Defense mechanisms against influenza virus infection in the respiratory tract mucosa. , 2004, Japanese journal of infectious diseases.

[97]  P. Woo,et al.  Viral Loads in Clinical Specimens and SARS Manifestations , 2004, Emerging infectious diseases.

[98]  P. Woo,et al.  Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus , 2004, Clinical Diagnostic Laboratory Immunology.

[99]  A. Lo,et al.  Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2) , 2004, The Journal of pathology.

[100]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[101]  G. Tse,et al.  Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in‐situ hybridization study of fatal cases , 2004, The Journal of pathology.

[102]  D. Eisen,et al.  Impact of mannose-binding lectin on susceptibility to infectious diseases. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[103]  A. Xu,et al.  Profile of specific antibodies to the SARS-associated coronavirus. , 2003, The New England journal of medicine.

[104]  M. van Herp,et al.  SARS and Carlo Urbani. , 2003, The New England journal of medicine.

[105]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[106]  D. Jack,et al.  Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS. , 2000, Gastroenterology.

[107]  David C. Nieman,et al.  Saliva immunoglobulins in elite women rowers , 2000, European Journal of Applied Physiology.

[108]  Wakamiya,et al.  Human mannan‐binding lectin inhibits the infection of influenza A virus without complement , 1999, Immunology.

[109]  D B Pyne,et al.  Salivary IgA levels and infection risk in elite swimmers. , 1999, Medicine and science in sports and exercise.

[110]  E. M. Peters,et al.  Exercise, Immunology and Upper Respiratory Tract Infections , 1997, International journal of sports medicine.

[111]  D. Nieman,et al.  Exercise, upper respiratory tract infection, and the immune system. , 1994, Medicine and science in sports and exercise.

[112]  G. Stoica,et al.  Influence of sex and age on serum immunoglobulin concentrations in healthy subjects. , 1978, Medecine interne.